NASDAQ:ALXN - Alexion Pharmaceuticals Stock Price, Price Target & More

Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."

Alexion Pharmaceuticals announced that its Board of Directors has initiated a stock repurchase program on Sunday, April 9th 2017, which allows the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 3.4% of its shares through open market purchases. Shares buyback programs are generally an indication that the company's leadership believes its stock is undervalued.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) released its quarterly earnings data on Thursday, April, 26th. The biopharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.50 by $0.18. The biopharmaceutical company earned $930.90 million during the quarter, compared to analyst estimates of $920.50 million. Alexion Pharmaceuticals had a net margin of 14.46% and a return on equity of 13.70%. The firm's revenue was up 7.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.38 EPS. View Alexion Pharmaceuticals' Earnings History.

Alexion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, July, 26th 2018. View Earnings Estimates for Alexion Pharmaceuticals.

Alexion Pharmaceuticals updated its FY18 earnings guidance on Thursday, April, 26th. The company provided earnings per share (EPS) guidance of $6.75-6.90 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.82. The company issued revenue guidance of $3.925-3.985 billion, compared to the consensus revenue estimate of $3.98 billion.

18 analysts have issued 12-month target prices for Alexion Pharmaceuticals' shares. Their predictions range from $130.00 to $180.00. On average, they expect Alexion Pharmaceuticals' share price to reach $161.1765 in the next twelve months. This suggests a possible upside of 19.8% from the stock's current price. View Analyst Ratings for Alexion Pharmaceuticals.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alexion Pharmaceuticals in the last year. There are currently 18 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Alexion Pharmaceuticals include Abbott Laboratories (ABT), Sanofi (SNY), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Allergan (AGN), Shire (SHPG), Vertex Pharmaceuticals (VRTX), Zoetis (ZTS), Regeneron Pharmaceuticals (REGN), Takeda Pharmaceutical (TKPYY) and Shiseido (SSDOY).

Media stories about ALXN stock have trended somewhat positive recently, according to Accern. The research group identifies negative and positive press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Alexion Pharmaceuticals earned a media sentiment score of 0.05 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 44.85 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Alexion Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Swedbank (0.37%), Bank of Montreal Can (0.30%), Peregrine Capital Management LLC (0.07%), Gateway Investment Advisers LLC (0.06%), Vigilant Capital Management LLC (0.04%) and Xact Kapitalforvaltning AB (0.02%). Company insiders that own Alexion Pharmaceuticals stock include Alvin S Parven, Ann M Veneman, Bros Advisors Lp Baker, Carsten Thiel, Christopher J Coughlin, Clare Carmichael, David Hallal, Edward Miller, Heidi L Wagner, John B Moriarty, John J Orloff, Julie O'neill, Leonard Bell, Ludwig Hantson, Paul J Clancy and Vikas Sinha. View Institutional Ownership Trends for Alexion Pharmaceuticals.

ALXN stock was sold by a variety of institutional investors in the last quarter, including Covenant Asset Management LLC, Handelsbanken Fonder AB, Gateway Investment Advisers LLC and Xact Kapitalforvaltning AB. Company insiders that have sold Alexion Pharmaceuticals company stock in the last year include Ann M Veneman, Heidi L Wagner, John B Moriarty, John J Orloff, Julie O'neill, Ludwig Hantson and Paul J Clancy. View Insider Buying and Selling for Alexion Pharmaceuticals.

ALXN stock was acquired by a variety of institutional investors in the last quarter, including Swedbank, Bank of Montreal Can, Vigilant Capital Management LLC, Bremer Trust National Association, State of Alaska Department of Revenue, IFM Investors Pty Ltd, Private Trust Co. NA and Campbell & CO Investment Adviser LLC. Company insiders that have bought Alexion Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, Christopher J Coughlin and Ludwig Hantson. View Insider Buying and Selling for Alexion Pharmaceuticals.

Shares of ALXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ALXN stock can currently be purchased for approximately $134.55.

Alexion Pharmaceuticals has a market capitalization of $30.23 billion and generates $3.55 billion in revenue each year. The biopharmaceutical company earns $443.30 million in net income (profit) each year or $5.16 on an earnings per share basis. Alexion Pharmaceuticals employs 2,525 workers across the globe.

Alexion Pharmaceuticals' mailing address is 100 COLLEGE STREET, NEW HAVEN CT, 06510. The biopharmaceutical company can be reached via phone at 475-230-2596.